JP2018533625A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533625A5
JP2018533625A5 JP2018543036A JP2018543036A JP2018533625A5 JP 2018533625 A5 JP2018533625 A5 JP 2018533625A5 JP 2018543036 A JP2018543036 A JP 2018543036A JP 2018543036 A JP2018543036 A JP 2018543036A JP 2018533625 A5 JP2018533625 A5 JP 2018533625A5
Authority
JP
Japan
Prior art keywords
hspc
cancer
seq
cells
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533625A (ja
JP6866385B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060273 external-priority patent/WO2017079400A1/en
Publication of JP2018533625A publication Critical patent/JP2018533625A/ja
Publication of JP2018533625A5 publication Critical patent/JP2018533625A5/ja
Priority to JP2021065361A priority Critical patent/JP7378439B2/ja
Application granted granted Critical
Publication of JP6866385B2 publication Critical patent/JP6866385B2/ja
Priority to JP2023097365A priority patent/JP2023115069A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2018543036A 2015-11-04 2016-11-03 造血幹細胞における遺伝子編集のための方法および組成物 Expired - Fee Related JP6866385B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021065361A JP7378439B2 (ja) 2015-11-04 2021-04-07 造血幹細胞における遺伝子編集のための方法および組成物
JP2023097365A JP2023115069A (ja) 2015-11-04 2023-06-14 造血幹細胞における遺伝子編集のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250561P 2015-11-04 2015-11-04
US62/250,561 2015-11-04
PCT/US2016/060273 WO2017079400A1 (en) 2015-11-04 2016-11-03 Methods and compositions for gene editing in hematopoietic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021065361A Division JP7378439B2 (ja) 2015-11-04 2021-04-07 造血幹細胞における遺伝子編集のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2018533625A JP2018533625A (ja) 2018-11-15
JP2018533625A5 true JP2018533625A5 (cg-RX-API-DMAC7.html) 2019-12-05
JP6866385B2 JP6866385B2 (ja) 2021-04-28

Family

ID=58662736

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543036A Expired - Fee Related JP6866385B2 (ja) 2015-11-04 2016-11-03 造血幹細胞における遺伝子編集のための方法および組成物
JP2021065361A Active JP7378439B2 (ja) 2015-11-04 2021-04-07 造血幹細胞における遺伝子編集のための方法および組成物
JP2023097365A Pending JP2023115069A (ja) 2015-11-04 2023-06-14 造血幹細胞における遺伝子編集のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021065361A Active JP7378439B2 (ja) 2015-11-04 2021-04-07 造血幹細胞における遺伝子編集のための方法および組成物
JP2023097365A Pending JP2023115069A (ja) 2015-11-04 2023-06-14 造血幹細胞における遺伝子編集のための方法および組成物

Country Status (17)

Country Link
US (3) US10548922B2 (cg-RX-API-DMAC7.html)
EP (1) EP3370741B1 (cg-RX-API-DMAC7.html)
JP (3) JP6866385B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180073679A (cg-RX-API-DMAC7.html)
CN (1) CN108463227A (cg-RX-API-DMAC7.html)
AU (2) AU2016349280B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018009098A8 (cg-RX-API-DMAC7.html)
CA (1) CA3004053A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018001198A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891092A1 (cg-RX-API-DMAC7.html)
HK (1) HK1259151A1 (cg-RX-API-DMAC7.html)
IL (1) IL259084A (cg-RX-API-DMAC7.html)
MX (1) MX2018005612A (cg-RX-API-DMAC7.html)
MY (1) MY185961A (cg-RX-API-DMAC7.html)
PH (1) PH12018500965A1 (cg-RX-API-DMAC7.html)
SG (2) SG10202107602XA (cg-RX-API-DMAC7.html)
WO (1) WO2017079400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
EP3025719B1 (en) 2014-11-26 2018-09-26 Miltenyi Biotec GmbH Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
SG11201803173VA (en) 2015-10-23 2018-05-30 Harvard College Nucleobase editors and uses thereof
KR20180073679A (ko) * 2015-11-04 2018-07-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 조혈 줄기 세포에서의 유전자 편집을 위한 방법 및 조성물
AU2017221456B2 (en) * 2016-02-19 2024-04-04 The Regents Of The University Of California Short hairpin RNA (shRNA734) and use of same to positively select and eliminate genetically modified cells
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
HRP20240842T1 (hr) * 2016-11-02 2024-10-11 Universität Basel Imunološki uočljive varijante stanične površine za upotrebu u staničnoj terapiji
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11975029B2 (en) * 2017-02-28 2024-05-07 Vor Biopharma Inc. Compositions and methods for inhibition of lineage specific proteins
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592C1 (en) 2017-10-16 2025-09-25 Beam Therapeutics, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
WO2019222545A1 (en) 2018-05-16 2019-11-21 Synthego Corporation Methods and systems for guide rna design and use
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
IL260445B (en) * 2018-07-05 2019-08-29 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
JP7716976B2 (ja) * 2018-09-19 2025-08-01 フジフィルム セルラー ダイナミクス，インコーポレイテッド キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
EP3873205A4 (en) * 2018-10-31 2022-05-11 Humanigen, Inc. MATERIALS AND METHODS FOR TREATMENT OF CANCER
CN109852627B (zh) * 2018-12-26 2022-07-05 中国人民解放军军事科学院军事医学研究院 用于CRISPRi系统的质粒、其构建方法及其在使鼠疫菌目的基因定向沉默中的应用
EP3911371A4 (en) * 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US20220202900A1 (en) * 2019-02-22 2022-06-30 The Trustees Of The University Of Pennsylvania Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia
WO2020181101A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
GB2601617B (en) 2019-03-19 2024-02-21 Broad Inst Inc Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN114729367A (zh) * 2019-08-28 2022-07-08 Vor生物制药股份有限公司 用于cll1修饰的组合物和方法
CN114787352A (zh) * 2019-08-28 2022-07-22 Vor生物制药股份有限公司 用于cd123修饰的组合物和方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
AU2020361683A1 (en) 2019-10-11 2022-05-19 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
KR20210109971A (ko) 2020-02-28 2021-09-07 현대자동차주식회사 리튬이온 전지 음극 제조방법 및 이에 의해 제조된 리튬이온 전지 음극을 포함하는 리튬이온 전지
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
KR20230126707A (ko) * 2020-12-31 2023-08-30 보르 바이오파마 인크. Cd34 유전자 변형을 위한 조성물 및 방법
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
KR20240004702A (ko) * 2021-04-28 2024-01-11 에자이 알앤드디 매니지먼트 가부시키가이샤 안티센스 올리고뉴클레오티드 및 신경퇴행성 장애의 치료를 위한 이들의 용도
EP4430186A1 (en) * 2021-11-09 2024-09-18 Vor Biopharma Inc. Compositions and methods for erm2 modification
WO2023091954A2 (en) 2021-11-19 2023-05-25 The Trustees Of The University Of Pennsylvania Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy
CA3247767A1 (en) * 2022-01-11 2023-07-20 Actinium Pharmaceuticals, Inc. METHODS FOR THE TREATMENT OF CD33 POSITIVE MALIGNANT HEMATIC DISEASE
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025059062A1 (en) * 2023-09-11 2025-03-20 The Trustees Of The University Of Pennsylvania Genetic engineering of human hematopoietic stem/progenitor cells (hspcs) for locus-specific expression of therapeutic proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515464A (ja) * 2007-01-11 2010-05-13 イエール・ユニバーシテイ Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法
CA2886684C (en) * 2012-10-10 2023-09-19 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
EP2958942B1 (en) * 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
JP6608807B2 (ja) * 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
ES2876263T3 (es) * 2014-04-07 2021-11-12 Novartis Ag Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
CN108290939B (zh) * 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
KR20180073679A (ko) * 2015-11-04 2018-07-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 조혈 줄기 세포에서의 유전자 편집을 위한 방법 및 조성물

Similar Documents

Publication Publication Date Title
JP2018533625A5 (cg-RX-API-DMAC7.html)
Jia et al. NK cell exhaustion in the tumor microenvironment
JP7273421B2 (ja) ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
Zhang et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Shimasaki et al. Expanded and armed natural killer cells for cancer treatment
Chang et al. Immune reconstitution after haploidentical hematopoietic stem cell transplantation
Li et al. CAR-NK cells for cancer immunotherapy: recent advances and future directions
JP2018500006A5 (cg-RX-API-DMAC7.html)
JP2017533706A5 (cg-RX-API-DMAC7.html)
IL259120A (en) Her2-targeted antigen chimeric receptors2
US20110020308A1 (en) Expression of transgenic t cell receptors in lak-t cells
JP2017533707A5 (cg-RX-API-DMAC7.html)
CN111989118A (zh) 包含耗竭性抗cd4单克隆抗体的抗癌t细胞治疗剂辅助用组合物及其用途
Golchin et al. Promotion of cell-based therapy: special focus on the cooperation of mesenchymal stem cell therapy and gene therapy for clinical trial studies
Zhang et al. Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
Fisher et al. T-regulatory cells for the treatment of autoimmune diseases
Garber et al. Adoptive T-cell therapy for Leukemia
Mondino et al. To remember or to forget: the role of good and bad memories in adoptive T cell therapy for tumors
CN112262212B (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
Motais et al. A bird’s-Eye View of Cell sources for cell-based therapies in blood cancers
Zhao et al. The role of mesenchymal stem cells in cancer immunotherapy
Kravets et al. Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy
Peng et al. The progress and perspectives of CAR-T cell therapy
Cao et al. Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells
Sona Next frontier in cancer treatment: an iPSC supported CAR-T cell therapies